Nufarm Limited Reports Lapse of 191,399 NUFAA Performance Rights Due to Unmet Vesting Conditions

Nufarm Submits Appendix 3H Confirming Expiry of 191,399 NUFAA Performance Rights

On 14 July 2026, Nufarm Limited lodged an Appendix 3H with the ASX, officially notifying the market of the expiry of 191,399 performance rights under the NUFAA security code. The Appendix 3H is the prescribed regulatory form for reporting the lapse, cancellation, or cessation of previously issued securities. These performance rights were unquoted equity securities, meaning they were not traded on the ASX like ordinary shares.

The cessation date was confirmed as 30 June 2026, coinciding with the end of the Australian financial year, consistent with typical performance right evaluation periods. Nufarm clarified that no payment or compensation would be made to holders of the lapsed rights, aligning with standard market practice when performance conditions remain unmet. The announcement also noted that issued capital figures might not fully reflect the current state if other ASX forms are under processing.

Reasons Behind the Failure of NUFAA Performance Rights to Vest by 30 June 2026

The company’s update explained that the 191,399 NUFAA performance rights lapsed because the attached vesting conditions were either not satisfied or became impossible to satisfy before the 30 June 2026 deadline. This regulatory phrasing covers scenarios where performance targets were tested and not achieved or where circumstances prevented target achievement altogether.

Nufarm did not disclose the specific performance criteria linked to the lapsed rights or identify the participants holding these rights. Typically, such performance rights are granted to senior executives and key management under long-term incentive plans, with vesting contingent on metrics like total shareholder return, earnings per share growth, or other financial and strategic benchmarks. The company did not specify the targets missed or the degree of underperformance in this announcement.

Updated Issued Capital Structure Following Performance Rights Lapse

Following the lapse, Nufarm’s capital structure, as detailed in Part 3 of the Appendix 3H, shows 384,257,570 ordinary fully paid shares under the NUF ticker. These shares represent the company’s quoted equity securities traded daily on the ASX and are used to calculate Nufarm’s market capitalization.

Regarding unquoted equity securities, 8,066,823 NUFAA performance rights remain outstanding after the lapse. These rights have yet to vest, be exercised, or lapse. The company cautioned that these figures might not fully represent the current issued capital if other ASX forms (Appendix 2A, 3G, or 3H) are concurrently being processed. Investors tracking dilution risk from Nufarm’s long-term incentive plan should consult the latest annual or remuneration reports for comprehensive details.

Implications of Lapsed Performance Rights on Nufarm’s Long-Term Incentive Program

The lapse of performance rights is a common occurrence among ASX-listed companies and does not inherently signal financial distress or a shift in corporate strategy. Instead, it reflects the intended operation of performance-based compensation schemes that align executive rewards with shareholder returns. When performance hurdles are unmet, the rights expire without value, consistent with governance best practices.

For Nufarm, which operates across crop protection, seed technologies, and omega-3 canola oil markets in Australia, New Zealand, Europe, and the Americas, the structure and outcomes of its long-term incentive plan are closely monitored by institutional investors and proxy advisors. The lapse of 191,399 rights reduces potential dilution for ordinary shareholders, as these rights will no longer convert into shares. However, the company did not disclose the financial year or grant cycle related to these rights or the forfeited value.

Overview of Nufarm’s Business Operations and Market Presence

Nufarm Limited is a diversified agricultural chemical and seed technologies company with operations spanning multiple continents. It produces and markets a wide range of herbicides, fungicides, insecticides, and plant growth regulators within its crop protection segment, serving farmers in Australia, New Zealand, North and South America, and Europe. Nufarm holds significant market positions across these regions.

Beyond traditional crop protection, Nufarm invests in seed technologies, including its proprietary omega-3 canola oil program, representing a strategic growth opportunity in the health and nutritional oils sector. The company’s revenue depends on agricultural input sales and is influenced by seasonal conditions, currency fluctuations, and regulatory approvals of active ingredients. These factors impact financial performance and, consequently, the ability to meet long-term incentive targets.

Regulatory and Governance Context of the Appendix 3H Filing

Filing an Appendix 3H is a mandatory ASX requirement whenever issued securities cease, including lapses of performance rights, option cancellations, or convertible instrument expiries. This obligation ensures investors and the market have accurate, up-to-date information on a company’s capital structure, promoting transparency and preventing reliance on outdated data.

Nufarm’s filing on 14 July 2026 satisfies its continuous disclosure duties regarding the 30 June 2026 cessation. The company, registered under ABN 37 091 323 312 and listed on the ASX as NUF, confirmed no consideration was paid upon cessation, consistent with typical terms of performance rights in ASX-listed firms where lapsed rights are extinguished without compensation.

Investor Considerations Regarding Reduced Outstanding Performance Rights

The lapse of 191,399 performance rights modestly benefits existing NUF shareholders by reducing potential dilution. When performance rights vest and convert into shares, they increase the total share count, diluting existing holdings. The expiry of these rights eliminates that dilution risk for this tranche.

With 8,066,823 NUFAA performance rights still outstanding, there remains potential for future share issuance if those rights vest. Investors concerned about dilution, earnings per share impact, or executive incentive structures should review Nufarm’s latest remuneration report, which details terms and performance conditions of outstanding rights. The immediate share price effect of this announcement was not evident from public data.

Summary of Key Dates and Capital Figures in Nufarm’s Appendix 3H Notice

The 14 July 2026 company update disclosed the cessation date for 191,399 NUFAA performance rights as 30 June 2026. Post-lapse, ordinary fully paid shares totaled 384,257,570, with 8,066,823 NUFAA performance rights remaining. No consideration was paid in relation to the cessation. The filing included Nufarm’s ABN (37 091 323 312) as part of standard entity identification. These details provide a precise snapshot of Nufarm’s issued capital as of the cessation date, subject to adjustments from concurrent ASX form processing.

Outlook: Monitoring Nufarm’s Incentive Plan and Capital Structure Updates

Investors and analysts should watch for future disclosures on Nufarm’s executive remuneration framework, including any new performance rights grants under the long-term incentive plan for the upcoming financial year. The company’s annual general meeting and annual report, featuring the remuneration report, are key sources for detailed information on equity-based incentive structures.

Subsequent Appendix 3H filings will signal further changes in outstanding performance rights through vesting, conversion, or additional lapses. Monitoring the NUF share register and NUFAA performance rights balance can provide insight into potential share issuance. The next major update on Nufarm’s financial performance and strategic direction will come from its forthcoming financial results or market announcements, offering broader context for performance hurdle assessments.